Publications
5539 Results
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS3629); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A022101
A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 11503); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
- Year
- 2023
A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS3640); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
A022104/NRG-GI010: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER | THE JANUS RECTAL CANCER TRIAL
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS4204); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021806
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS8603); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma (Alliance A092001)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr TPS3641); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
A Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer (Alliance A022004)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 1076); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Breast
- Study Number(s)
- S0226
Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5074); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Prostate-Specific Antigen at 3 & 7 months (PSA-3mo, PSA-7mo) Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation With or Without Orteronel (SWOG S1216)
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 5080); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 16; abstr 4562); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
- Year
- 2023
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1500